Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007

Formosa Pharmaceuticals and Rxilient Medical Pte have entered into an exclusive licensing agreement for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Additionally, the agreement includes upfront regulatory milestones and sales milestones.

APP13007 was approved by the US Food and Drug Administration (FDA) in March 2024. It offers a twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain.

APP13007's active ingredient is the “superpotent” corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT nanoparticle formulation platform. The company noted that in a US survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free 4 days post-surgery) and low incidence of adverse events (<2%) were highlighted as key reasons for prescribing APP13007.

Erick Co, president and CEO of Formosa Pharmaceuticals, and Lawrence He, CEO of Rxilient, commented on the partnership in a press release.

"We are pleased to establish this partnership with Rxilient, a prominent and growing regional corporation with global experience. We are confident that Rxilient's foundation, network, and commitment to innovative medicines will bring APP13007 to patients recovering from ocular surgery,” said Co.

"At Rxilient, we strive to offer high-quality therapies to patients in our region to serve their unmet needs. We are pleased to partner with Formosa and bring APP13007 to our markets and provide solutions to patients recovering from ocular surgery," added He.

Eyenovia acquired US commercial rights to the drug in August 2023 from Formosa. Cristália Products Químicos Farmacêuticos LTDA acquired exclusive Brazilian rights from Formosa in January 2024. In Canada, Apotex Inc. acquired exclusive rights in August 2024.

References:

1. Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular. Published December 3, 2025. Accessed December 3, 2025. https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-rxilient-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302631552.html